Genetic Predictors of AML Treatment Response
- Perform a genome-wide scan to test for loci associated with acute myeloid leukemia
(AML) relapse and infection risk.
- Validate positive associations seen in the genome-wide scan with a fine mapping
- Perform simulated clinical trials using germline genetic variation data to test the
feasibility of using genetic data to inform the clinical care of pediatric patients
OUTLINE: This is a multicenter study.
Germline DNA is obtained from previously collected peripheral blood or bone marrow samples
for array-based genotyping studies, including genome-wide association studies (single
nucleotide polymorphisms) and fine mapping genotyping.
Clinical trial simulations are performed to test the clinical applicability of using genetic
variation data in the management of infectious complications.
First acute myeloid leukemia relapse
Richard Aplenc, MD, MSCE
Children's Hospital of Philadelphia
United States: Federal Government